Fit and well (finding)

D0001 Swine Flu (Novel Influenza A H1N1) Vaccine Study

Year Started: 2009

Two new vaccines (Baxter swine flu & GSK swine flu vaccine) have been made against swine flu in response to the pandemic. These vaccines have been tested in adults, but there is less information on how well they work in children. This study will assess these two new vaccines in children aged between six months and twelve years



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 11 - 25%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 11 - 25%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 11 - 25%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 0 - 10%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 0 - 10%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 11 - 25%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0008 Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 years of age

Year Started: 2009

D0008 Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 years of age



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 11 - 25%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 11 - 25%
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 11 - 25%


Male

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%
Serum -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0009 Study to evaluate the induction of immune memory following infant vaccination with a glycol-conjugate Neisseria Meningitidis serogroup C Vaccine

Year Started: 2011

Please note, this collection consists of blood clots but it is listed as plasma. Study to evaluate the induction of immune memory following infant vaccination with a glycol-conjugate Neisseria Meningitidis serogroup C Vaccine and to assess the immune response to the concurrent infant routine immunisations administered in consistent versus alternating limbs.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 11 - 25%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
DNA -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0010 Comparison study of two H1N1 influenza vaccines in children

Year Started: 2010

A multi-centre, open-label, clinical, phase 4 trial, following on from a head-to-head comparison study of two H1N1 influenza vaccines in children, to compare firstly, the persistence of antibody against the A/California/7/2009 (H1N1) virus and secondly the immunogenicity and reactogenicity of one dose of a non-adjuvanted trivalent seasonal influenza vaccine, in children who had received a two-dose immunisation regimen of Celvapan or Pandemrix.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 26 - 50%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%


Female

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0011 Swine Flu (Influenza A H1N1) Follow on Vaccine Study

Year Started: 2010

A multi-centre, open-label, clinical, phase 4 trial, following on from a head-to-head comparison study of two H1N1 influenza vaccines in children, to compare firstly, the persistence of antibody against the A/California/7/2009 (H1N1) virus and secondly the immunogenicity and reactogenicity of one dose of a non-adjuvanted trivalent seasonal influenza vaccine, in children who had received a two-dose immunisation regimen of Celvapan or Pandemrix.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 26 - 50%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 26 - 50%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0013 Pilot study to evaluate the kinetics of the systemic B-cell response to a meningococcal serogroup C conjugate vaccine in healthy adults

Year Started: 2006

Meningitis and septicaemia (blood poisoning) caused by the bacterium Neisseria meningitidis (meningococcus) remain important causes of death and disability amongst children and younger adults in the UK and elsewhere. The bacteria can be carried on the mucous membranes in the back of the nose and mouth without causing any symptoms. This so-called carriage state is found in around 10% of the population of the UK at any one time. The bacteria are spread through person to person contact and only occasionally does this spread lead to the development of meningitis and septicaemia rather than carriage. The reasons behind this are not clearly understood. A vaccine against meningococcus group C (Men C), one of five groups of the bacteria that can cause disease, was introduced into the UK in 1999 and led to a sharp drop in the rates of meningitis and septicaemia. The vaccine also led to a decrease in the rates of carriage of the bacteria. This suggests that the vaccine not only generates immune protection preventing meningitis and septicaemia but also generates immunity in the back of the nose and mouth preventing carriage. The way the vaccine generates this “mucosal immunity” is not known and is the topic of our research. This study is the first part of a research programme and aims to identify the way the vaccine works in the blood.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 26 - 50%


Female

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%


Male

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 11 - 25%


Male

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%

Fit and well (finding)

D0014 Study to evaluate the mucosal immune response to Novartis Meningococcal ACWY conjugate vaccine in healthy adults undergoing tonsillectomy

Year Started: 2007

Meningitis and septicaemia (blood poisoning) caused by Neisseria meningitidis (meningococcus) remain important causes of death and disability amongst children and younger adults in the UK and elsewhere. The bacteria can also be carried, without causing symptoms, on the mucous membranes in the back of the nose and mouth. This so-called “carriage state” is found in around 10% of the population of the UK at any one time. The bacteria is spread through person to person contact and only occasionally does this spread lead to the development of meningitis and septicaemia rather than carriage. The reasons behind this are not clearly understood. A vaccine against group C meningococcus (Men C), one of five groups of the bacteria that can cause disease, was introduced into the UK in 1999 and led to a sharp drop in the rates of meningitis and septicaemia. The vaccine also led to a decrease in the number of people carrying the bacteria in the back of the mouth and nose. This suggests that the vaccine not only generates immunity preventing meningitis and septicaemia, but also generates immune protection in the back of the nose and mouth, preventing the carriage state. This prevention of carriage may be central to the way the vaccine works, as it stops the bacteria circulating from person to person and therefore stops its spread within the population as a whole. The way the vaccine generates this protection in the back of the nose is not known. We hope that this research will help us to better understand this important question. We are using a vaccine of the same type as the Men C vaccine already widely used in the UK. However, instead of covering just one group of meningococcus (group C), the vaccine we are using covers four of the five groups of meningococcus that are known to cause disease (groups A, C, W135 and Y). The vaccine is manufactured and provided to us by Novartis Vaccines, a commercial vaccine manufacturer. It is not yet licensed for use and other studies using the vaccine are ongoing in Europe and in Latin America. We will be comparing the immune response generated by the vaccine in the tonsils (at the back of the nose and mouth) to that occurring in the blood.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 11 - 25%


Female

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 51 - 75%


Male

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 11 - 25%

Fit and well (finding)

D0015 Improved diagnosis of meningococcal, pneumococcal and group A streptococcal infections

Year Started: 2005

Improved diagnosis of meningococcal, pneumococcal and group A streptococcal infections



Access:
Access restricted at present
Type:
Disease specific
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young adult (18 - 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0016 Server, unusual, or recurrent community acquired infection in children- susceptibility, detection and immune response (CAI)

Year Started: 2006

What makes the bug choose your child, how can we find it and how can we stop it? The study is trying to improve our understanding of why some children get sick when others don’t, even though they must have been exposed to the same bugs. We are also trying to develop ways of finding out what has caused an infection, using ways which don’t rely on finding the bug itself (one example of this would be to test urine for evidence of the bug for example). The other part of the study is to use the information we can get from children who are infected by these bugs to help develop vaccines to increase our ability to prevent infections in the first place.



Access:
Access restricted at present
Type:
Disease specific
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Urine -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 11 - 25%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young adult (18 - 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Saliva -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0022 Study to evaluate the immunogenicity and safety of a booster dose of Boostrix Polio compared with Repevax, when coadministered with Priorix in 3 and 4-year-old healthy children

Year Started: 2011

Please note, this collection consists of blood clots but it is listed as plasma. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi Pasteur MSD’s dTpa-IPV vaccine (Repevax), when coadministered with GSK Biologicals’ MMR vaccine (Priorix) in 3 and 4-year-old healthy children.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 26 - 50%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 51 - 75%

Fit and well (finding)

D0023 Study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A (FLU D-QIV), administered intramuscularly in children 9 to 35 months of age

Year Started: 2011

Please note, this collection consists of blood clots but it is listed as plasma. Study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A (FLU D-QIV), administered intramuscularly in children 9 to 35 months of age.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 26 - 50%


Female

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 26 - 50%

Fit and well (finding)

D0024 Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1

Year Started: 2013

Please note, this collection consists of blood clots but it is listed as plasma. A new vaccine has been developed by Novartis Vaccines and Diagnostics S.r.l. (“Novartis Vaccines”) aimed at preventing MenB disease. The vaccine is “investigational”, meaning that it has been approved for use in the study but that it is not licensed for routine use. In 2008-2009 a study of this MenB vaccine, enrolling 1,800 children, was conducted in the UK and other European countries. Of these, 1,510 children participated in a follow-on study, receiving a further dose of MenB at 12, 18, or 24 months of age. In addition 3 control groups received 2 doses of the MenB vaccine, 2 months apart, at 12, 18 or 24 months of age. Children who have completed this study are now being approached to take part in a second ‘follow-on’ study in which the majority of children will receive one further dose of the MenB vaccine at around 4 years of age. The aim of this follow-on study is to assess whether children immunised as infants and/or toddlers with the MenB vaccine have maintained high levels of antibodies against MenB germs until they are around 4 years of age. We would also like to assess how well children respond to a further dose of the MenB vaccine. In addition we will be monitoring the safety of the MenB vaccine.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 26 - 50%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 51 - 75%

Fit and well (finding)

D0025 Broader protection against pneumococcal disease: a follow-on study

Year Started: 2010

Please note, this collection consists of blood clots but it is listed as plasma. During the initial study your child received one of 2 pneumococcal vaccines; either the 7-valent pneumococcal vaccine (PCV7) which protects against 7 types of pneumococcal bacteria, or the new 13-valent pneumococcal vaccine (PCV13) protecting against 13 types of pneumococcus which has recently replaced PCV7 in the routine immunisation schedule. The PCV13 vaccine has been shown to produce an immune response against 13 types of pneumococcus and therefore provides a broader level of protection than the PCV7 vaccine. It is now important to determine how well the immune response to the PCV13 vaccine persists throughout childhood. To do this we would like to take a sample of blood from children, who participated in the original study, when they are approximately 3 ½ years of age. We would also like to study the response to a dose of PCV13 vaccine when given to children who were immunised with either PCV7 or PCV13 as an infant.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 26 - 50%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 51 - 75%

Fit and well (finding)

D0026 Study to evaluate V419 (PR5I) given at 2, 3 & 4 months with two types of meningococcal serogroup C conjugate (MCC) vaccines given at 3 & 4 months, followed by a combined Haemophilus influenza type b-MCC vaccine at 12 months

Year Started: 2012

Please note, this collection consists of blood clots but it is listed as plasma. A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal serogroup C conjugate (MCC) vaccines given at 3 an 4 months of age, and followed by the administration at 12 months of age of a combined Haemophilus influenza type b-MCC vaccine.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 51 - 75%


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 26 - 50%

Fit and well (finding)

D0027 Sample collection from healthy volunteers

Year Started: 2013

Saliva, urine, nasopharyngeal swabs & nasal washes may be obtained from healthy donors of all ages, but mostly from children and young adults.



Access:
Access restricted at present
Type:
Population-based
Status:
In progress
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C N/A Not applicable 26 - 50%


Female

Young adult (18 - 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C N/A Not applicable 11 - 25%


Male

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C N/A Not applicable 11 - 25%


Male

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0032 The Bristol Nasal Colonisation Surveillance Study

Year Started: 2011

The effects of viral upper respiratory tract infections on bacterial colonisation of the nasopharynx in young healthy children attending day care centres. A single centre prospective longitudinal follow up study.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 26 - 50%


Male

Infant (1 month - 2 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 26 - 50%


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C N/A Not applicable 0 - 10%


Male

Infant (1 month - 2 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C N/A Not applicable 0 - 10%

Fit and well (finding)

D0034 The effects of live attenuated trivalent intranasal influenza vaccine on nasopharyngeal bacterial colonisation in healthy children aged 2-4 years attending day care centres

Year Started: 2011

The effects of live attenuated trivalent intranasal influenza vaccine on nasopharyngeal bacterial colonisation in healthy children aged 2-4 years attending day care centres. A single centre, randomised intervention study.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Young child (2 - 6 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 26 - 50%


Male

Young child (2 - 6 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 26 - 50%

Fit and well (finding)

D0036 Human responses to candidate pneumococcal vaccines (“PATH longitudinal study”)

Year Started: 2008

Samples were collected as part of the “PATH longitudinal study” from a total of 60 healthy children aged 0-16 years when they were undergoing routine adenoidectomy or adenotonsillectomy surgery.



Access:
Access restricted at present
Type:
Disease specific
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Child (6 - 12 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 11 - 25%


Male

Child (6 - 12 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 11 - 25%


Male

Young child (2 - 6 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 26 - 50%


Male

Adolescent (12 - 18 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Swab -60°C to -85°C N/A Not applicable 0 - 10%


Female

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 26 - 50%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 26 - 50%


Male

Young child (2 - 6 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 26 - 50%


Female

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) -60°C to -85°C N/A Not applicable 11 - 25%


Female

Young child (2 - 6 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) -60°C to -85°C N/A Not applicable 26 - 50%


Male

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) -60°C to -85°C N/A Not applicable 26 - 50%